Sermorelin vs CJC-1295 vs Ipamorelin: Anti-Aging GH Peptide Decision Guide

The Two Pathways: GHRH vs GHRP

Understanding GH peptide selection requires knowing how your body normally releases growth hormone. Two signaling systems control pituitary GH secretion:

GHRH Pathway (Growth Hormone-Releasing Hormone)

Your hypothalamus secretes GHRH, which binds to GHRH receptors on pituitary somatotrophs, triggering GH synthesis and release. Sermorelin and CJC-1295 are GHRH analogs — they mimic this natural signal.

Key characteristic: GHRH analogs amplify the existing GH pulse. They work best when the body is already primed to release GH (during sleep, after exercise, during fasting).

GHRP Pathway (Growth Hormone-Releasing Peptide / Ghrelin Mimetic)

The ghrelin receptor (GHS-R1a) on pituitary cells provides a separate stimulatory input for GH release. Ipamorelin is a ghrelin mimetic — it activates this parallel pathway.

Key characteristic: GHRPs can initiate a GH pulse even when GHRH tone is low. They create GH release regardless of the body's current signaling state.

Why Stacking Works

Because these pathways converge on the same pituitary somatotroph cells through different receptors, activating both simultaneously produces synergistic GH release — not just additive, but multiplicative (Bowers et al., 1984, Endocrinology). This is why the CJC-1295 + Ipamorelin combination is the gold standard in anti-aging clinics.

---

Sermorelin (GRF 1-29): The First Generation

What It Is

Sermorelin is the first 29 amino acids of natural GHRH (which is 44 amino acids total). These 29 residues contain the full biologically active sequence — amino acids 30-44 are not required for receptor binding. It was developed in the 1980s and received FDA approval for pediatric growth hormone deficiency before being discontinued for commercial (not safety) reasons.

Mechanism

Sermorelin binds to the GHRH receptor on anterior pituitary somatotrophs, stimulating:

• GH gene transcription (making more GH protein)
• GH vesicle release (secreting stored GH)
• Somatotroph proliferation (growing more GH-producing cells over time)

Pharmacokinetics

• Half-life: ~10-20 minutes (very short)
• Peak GH release: 15-30 minutes post-injection
• Duration of effect: ~60-90 minutes
• Administration: Subcutaneous injection, typically before bed

Clinical Evidence

Sermorelin has the most clinical data of the three:

• Walker et al. (2006) demonstrated increased IGF-1 and improved body composition in GH-deficient adults
• Vittone et al. (1997) showed improved sleep quality and REM architecture
• Khorram et al. (2001) documented improvements in lean body mass and skin thickness in elderly subjects over 6 months

Dosing Protocol

• Standard anti-aging: 200-300mcg subcutaneous before bed
• Aggressive protocol: 200-300mcg twice daily (morning + before bed)
• Cycling: 5 days on / 2 days off, or 3 months on / 1 month off
• Loading: Some clinics use 500mcg/night for first 2 weeks

Advantages

1. Most clinical data — decades of research, FDA history
2. Preserves natural pulsatility — works with your body's rhythms
3. Low side effect profile — injection-site reactions most common
4. No significant cortisol or prolactin elevation (unlike some GHRPs)
5. Suitable for long-term use — no desensitization at standard doses

Limitations

1. Very short half-life — GH pulse is brief
2. Requires optimal somatostatin tone — if somatostatin is high (stress, high glucose), response is blunted
3. Manufacturing discontinued — now primarily from compounding pharmacies and research suppliers
4. Less potent than newer analogs per-injection

[Internal Link: /sermorelin/]

---

CJC-1295 (Modified GRF 1-29): The Optimized GHRH

What It Is

CJC-1295 without DAC (also called mod GRF 1-29 or tetrasubstituted GRF 1-29) is Sermorelin with four amino acid substitutions at positions 2, 8, 15, and 27. These modifications dramatically improve enzymatic stability — the peptide resists degradation by dipeptidyl peptidase-IV (DPP-IV) and other proteases that rapidly destroy native GHRH and Sermorelin (Teichman et al., 2006, J Clin Endocrinol Metab).

Important distinction: "CJC-1295" in the bodybuilding/peptide community almost always refers to the version without DAC (Drug Affinity Complex). CJC-1295 with DAC is a different pharmacological animal — see below.

Mechanism

Identical to Sermorelin (GHRH receptor agonism on pituitary somatotrophs). The improvement is purely pharmacokinetic — longer survival in the bloodstream means more sustained receptor activation.

Pharmacokinetics

• Half-life: ~30 minutes (vs Sermorelin's ~10-20 minutes)
• Peak GH release: 20-40 minutes post-injection
• Duration of effect: ~2-3 hours
• Administration: Subcutaneous injection, typically before bed or post-workout

CJC-1295 with DAC: The Weekly Option

CJC-1295 with DAC (Drug Affinity Complex) binds to albumin in the blood, extending its half-life to 6-8 days. This allows once-weekly dosing. However, it creates a continuous "bleed" of GHRH stimulation rather than discrete pulses — which may cause pituitary desensitization over time and doesn't mimic natural physiology.

With DAC: Convenient (weekly dosing), but potentially less physiological Without DAC: Requires daily injection, but preserves natural GH pulsatility

Most anti-aging practitioners prefer CJC-1295 without DAC for this reason.

Dosing Protocol

• Standard (without DAC): 100-200mcg subcutaneous before bed
• Stacked with Ipamorelin: 100mcg CJC + 100-200mcg Ipamorelin (same syringe)
• Post-workout: Additional 100mcg injection (optional second daily dose)
• Cycling: 5/2 split or 8 weeks on / 4 weeks off

Advantages Over Sermorelin

1. 3x longer half-life — more sustained GH pulse
2. More resistant to degradation — consistent absorption regardless of injection site conditions
3. Better synergy with GHRPs — the extended action window overlaps more completely with Ipamorelin
4. Dose-response predictability — less variable between users due to enzymatic stability

Limitations

1. Less clinical data than Sermorelin — most evidence is from bodybuilding/anti-aging community reports
2. Still requires daily injection (without DAC version)
3. Cost: Slightly more expensive per mg than Sermorelin
4. Same somatostatin sensitivity — still blunted by high somatostatin tone

[Internal Link: /cjc-1295/]

---

Ipamorelin: The Clean GHRP

What It Is

Ipamorelin is a pentapeptide (5 amino acids) growth hormone secretagogue (GHS) that acts as a selective ghrelin receptor (GHS-R1a) agonist. Among all GHRPs (GHRP-2, GHRP-6, hexarelin, ipamorelin), it has the cleanest side effect profile — meaning it stimulates GH release with minimal impact on cortisol, prolactin, and appetite (Raun et al., 1998, Eur J Endocrinol).

Mechanism

Ipamorelin binds to the ghrelin receptor on pituitary somatotrophs, amplifying GH release through a pathway independent of GHRH. It also suppresses somatostatin (the GH-inhibiting hormone), further potentiating GH output.

Unlike GHRP-6 and GHRP-2, ipamorelin does NOT significantly activate the ghrelin receptor's appetite-stimulating downstream effects at therapeutic doses.

Pharmacokinetics

• Half-life: ~2 hours
• Peak GH release: 30-45 minutes post-injection
• Duration of elevated GH: ~3-4 hours
• Administration: Subcutaneous injection

Why "Cleanest GHRP" Matters

Compare side effects across the GHRP class:

Ipamorelin gives you reliable GH stimulation without the ravenous hunger of GHRP-6, the cortisol bump of hexarelin, or the prolactin concerns of GHRP-2. This makes it suitable for long-term anti-aging use where you don't want secondary hormonal disruption.

Dosing Protocol

• Standard: 100-300mcg subcutaneous before bed
• Stacked with CJC-1295: 100-200mcg Ipamorelin + 100mcg CJC-1295 (same syringe)
• Fat loss focus: 200-300mcg three times daily (pre-breakfast, post-workout, before bed)
• Cycling: 5/2 split or continuous use for 3-6 months

Advantages

1. Cleanest side effect profile — no hunger, cortisol, or prolactin spikes
2. Selective GH release — doesn't promiscuously activate other hormone pathways
3. Synergistic with GHRH analogs — the CJC + Ipa combo is greater than the sum
4. Long-term tolerability — minimal desensitization at standard doses
5. Versatile timing — can dose multiple times daily without cortisol accumulation

Limitations

1. Less potent alone than GHRP-2 or hexarelin for pure GH output
2. Best results require GHRH pairing — standalone is good, combined is great
3. Limited human clinical trials — most data from animal models and practitioner experience
4. Cost per mg is moderate — more expensive than GHRP-6 but comparable to CJC

[Internal Link: /ipamorelin/]

---

The Gold Standard Stack: CJC-1295 + Ipamorelin

This combination has become the standard of care in anti-aging medicine for GH optimization. Here's why the synergy works:

The Science of Synergy

CJC-1295 (GHRH analog) primes the somatotroph cell by:

• Increasing intracellular cAMP
• Loading GH vesicles to the cell membrane
• Initiating GH gene transcription

Ipamorelin (ghrelin mimetic) triggers the release by:

• Activating protein kinase C pathway
• Opening calcium channels
• Releasing the "primed" GH vesicles

Together, one peptide loads the gun (CJC) and the other pulls the trigger (Ipamorelin). The GH pulse from the combination is 2-3x greater than either alone (synergistic, not merely additive).

Standard Combined Protocol

Before bed (primary dose):

• CJC-1295 (no DAC): 100mcg
• Ipamorelin: 100-200mcg
• Combined in same syringe (bacteriostatic water)
• On empty stomach (no food for 2 hours prior — glucose/insulin blunt GH release)

Optional morning dose:

• Same doses, 30 minutes before breakfast
• Fasted state required

Cycling:

• 5 days on / 2 days off (weekdays on, weekends off)
• Or: 8 weeks on / 4 weeks off
• Or: continuous at lower doses (100+100mcg nightly)

---

Patient Profile Matching: Who Should Use What

Pure Anti-Aging (40-60 years, general wellness)

Best choice: CJC-1295 + Ipamorelin stack Why: Safest long-term profile, synergistic, maintains physiological pulsatility Protocol: 100mcg each, nightly before bed, 5/2 cycling Expected results: Improved sleep quality (4-6 weeks), body composition shifts (8-12 weeks), skin/hair improvements (12-16 weeks)

Fat Loss Focus

Best choice: CJC-1295 + Ipamorelin (higher dose, multiple daily) Why: GH is lipolytic; more frequent pulses = more fat mobilization Protocol: 150mcg each, three times daily (fasted morning, pre-workout, bedtime) Stack with: Semaglutide for appetite suppression + peptide GH for lean mass preservation Expected results: Accelerated fat loss while preserving muscle, particularly effective for visceral fat

[Internal Link: /semaglutide/]

Post-Injury Recovery

Best choice: Ipamorelin (higher dose) + BPC-157 Why: GH accelerates tissue repair; BPC-157 provides local healing signaling Protocol: Ipamorelin 300mcg 2x/day + BPC-157 250-500mcg near injury site 2x/day Duration: 4-8 weeks or until recovery complete

[Internal Link: /bpc-157/]

Best-Studied (Conservative Approach)

Best choice: Sermorelin Why: Most clinical data, FDA approval history, decades of safety profile Protocol: 200-300mcg nightly before bed Ideal for: Patients who prioritize evidence base over potency, physicians new to peptide therapy

Most Convenient (Minimal Injections)

Best choice: CJC-1295 with DAC Why: 6-8 day half-life allows weekly dosing Protocol: 1-2mg once weekly, subcutaneous Trade-off: Less physiological (continuous stimulation vs pulsatile), potential for desensitization Best for: Patients who won't comply with daily injections

Maximum GH Output (Bodybuilding)

Best choice: CJC-1295 + GHRP-2 (or Ipamorelin at higher doses) Why: GHRP-2 is more potent than Ipamorelin for raw GH release Protocol: CJC 200mcg + GHRP-2 200mcg, 3x/day (accept hunger and mild cortisol increase) Trade-off: More side effects than Ipamorelin combo, but greater GH output

---

Cost Comparison (Canadian Market, 2026)

The peptide approach is roughly 5-10x cheaper than pharmaceutical HGH while achieving 60-80% of the IGF-1 elevation.

---

Side Effects and Safety

Common Across All Three

• Injection site reactions (redness, itching) — transient
• Water retention (mild, especially first 2-4 weeks)
• Tingling/numbness in extremities (carpal tunnel-like, from GH elevation)
• Increased hunger (mild with Ipamorelin, moderate with Sermorelin/CJC)

When to Get Bloodwork

• Baseline: IGF-1, fasting glucose, fasting insulin, HbA1c
• 4-week check: IGF-1 (confirm response)
• 12-week check: Full panel including glucose/insulin (GH can impair insulin sensitivity at high levels)

Contraindications

• Active cancer or history of cancer (GH/IGF-1 may promote tumor growth)
• Uncontrolled diabetes (GH antagonizes insulin)
• Active retinopathy
• Pregnancy/breastfeeding

---

Frequently Asked Questions

Can I use GH peptides alongside TRT or a steroid cycle?

Yes. GH peptides and anabolic steroids work through completely different mechanisms. Many users run CJC+Ipamorelin throughout their TRT or steroid cycles for enhanced recovery and body composition. The GH elevation actually synergizes with androgens for lean tissue accretion and fat loss. No dose adjustment is needed for the peptides when adding AAS.

How long until I notice results from GH peptides?

Sleep improvement is typically the first benefit — deeper sleep, more vivid dreams — within 1-2 weeks. Body composition changes (fat loss, muscle quality) require 8-12 weeks of consistent use. Skin, hair, and nail improvements take 12-16 weeks. Anti-aging/longevity benefits are cumulative over 6-12+ months.

Do GH peptides shut down my natural GH production?

No — this is their key advantage over exogenous HGH. Peptides stimulate your own pituitary to produce GH. They work with your feedback system, not against it. When you stop, your GH production returns to baseline (it doesn't go below baseline). There's no "PCT" needed for GH peptides.

Should I take GH peptides on an empty stomach?

Yes. Insulin and glucose blunt GH release. For maximum effect, inject at least 90 minutes after eating (ideally 2+ hours). Bedtime dosing works well because most people haven't eaten for 2-3 hours before sleep. Morning dosing should be immediately upon waking, before any food.

What's the difference between research-grade and pharmaceutical-grade peptides?

In Canada, pharmaceutical-grade Sermorelin was previously available but is now primarily through compounding pharmacies. CJC-1295 and Ipamorelin have never had pharmaceutical approval — they exist only as research chemicals or compounding pharmacy preparations. Quality varies significantly between suppliers. Look for: third-party HPLC testing (>98% purity), proper lyophilization, and appropriate storage (shipped cold). Avoid pre-mixed "ready to inject" solutions — legitimate peptides are sold as lyophilized powder requiring reconstitution.

[Internal Link: /peptide-reconstitution-guide/]

---

Conclusion: Choosing Your GH Peptide Protocol

The growth hormone peptide landscape in 2026 is mature enough that we can match protocols to patients with confidence:

• New to peptides, want safety data: Start with Sermorelin. Most clinical evidence, predictable response, excellent safety record.
• Optimizing for results: CJC-1295 + Ipamorelin stack. The synergistic combination is the consensus standard for a reason — it works better than either alone.
• Convenience priority: CJC-1295 with DAC for weekly dosing. Accept slightly less physiological pulsing in exchange for simplicity.
• Fat loss primary goal: CJC + Ipa at higher doses, multiple daily injections, stacked with a GLP-1 agonist.
• Recovery from injury: Ipamorelin + BPC-157 targeted protocol.

Regardless of which you choose, the principles remain constant: inject on an empty stomach, dose before bed for maximum synergy with natural nocturnal GH secretion, get baseline and follow-up IGF-1 labs, and commit to at least 8-12 weeks before judging results.

[Internal Link: /peptide-stacks/] [Internal Link: /anti-aging-protocols/]

---

Disclaimer: This article is for educational purposes only. Peptide therapies should be pursued under medical supervision. Growth hormone secretagogues are not approved by Health Canada for anti-aging use. Consult a qualified healthcare provider before beginning any peptide protocol.